227 related articles for article (PubMed ID: 20056944)
1. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.
De Keulenaer GW; Doggen K; Lemmens K
Circ Res; 2010 Jan; 106(1):35-46. PubMed ID: 20056944
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
3. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
4. Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure.
Doggen K; Ray L; Mathieu M; Mc Entee K; Lemmens K; De Keulenaer GW
J Mol Cell Cardiol; 2009 Jan; 46(1):33-8. PubMed ID: 19010331
[TBL] [Abstract][Full Text] [Related]
5. Neuregulin receptors erbB2 and erbB4 in failing human myocardium -- depressed expression and attenuated activation.
Rohrbach S; Niemann B; Silber RE; Holtz J
Basic Res Cardiol; 2005 May; 100(3):240-9. PubMed ID: 15685397
[TBL] [Abstract][Full Text] [Related]
6. Neuregulin-1/ErbB signaling and chronic heart failure.
Xu Y; Li X; Liu X; Zhou M
Adv Pharmacol; 2010; 59():31-51. PubMed ID: 20933198
[TBL] [Abstract][Full Text] [Related]
7. Neuregulin-1/ErbB signaling: a druggable target for treating heart failure.
Xu Y; Li X; Zhou M
Curr Opin Pharmacol; 2009 Apr; 9(2):214-9. PubMed ID: 19070544
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line.
Frohnert PW; Stonecypher MS; Carroll SL
Glia; 2003 Aug; 43(2):104-18. PubMed ID: 12838503
[TBL] [Abstract][Full Text] [Related]
9. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
Kunz C; Borghouts C; Buerger C; Groner B
Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
[TBL] [Abstract][Full Text] [Related]
10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
11. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
[TBL] [Abstract][Full Text] [Related]
13. Interaction and inhibitory cross-talk between endothelin and ErbB receptors in the adult heart.
Chung KY; Walker JW
Mol Pharmacol; 2007 Jun; 71(6):1494-502. PubMed ID: 17332141
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the neuregulins and their receptors in cardiac and neural development.
Carraway KL
Bioessays; 1996 Apr; 18(4):263-6. PubMed ID: 8967893
[TBL] [Abstract][Full Text] [Related]
15. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Chen FL; Xia W; Spector NL
Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
[TBL] [Abstract][Full Text] [Related]
17. ErbB family targeting.
Black JD; Brattain MG; Krishnamurthi SA; Dawson DM; Willson JK
Curr Opin Investig Drugs; 2003 Dec; 4(12):1451-4. PubMed ID: 14763131
[TBL] [Abstract][Full Text] [Related]
18. ErbB2 and EGFR are downmodulated during the differentiation of 3T3-L1 preadipocytes.
Pagano E; Calvo JC
J Cell Biochem; 2003 Oct; 90(3):561-72. PubMed ID: 14523990
[TBL] [Abstract][Full Text] [Related]
19. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
20. BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells.
Egeblad M; Mortensen OH; van Kempen LC; Jäättelä M
Biochem Biophys Res Commun; 2001 Feb; 281(1):25-31. PubMed ID: 11178955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
